Fosamax and Osteonecrosis of the Jaw: Understanding the Medical Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Drug Safety

The legacy of general health and science information has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this broad context, the dissemination of knowledge regarding pharmaceutical interventions, including their potential adverse effects, has been a central concern. Historically, such information has been curated for a general audience, emphasizing balanced perspectives on treatment outcomes and patient safety. This heritage provides a critical framework for examining specific drug-safety questions that arise in clinical practice and public health discourse. Transitioning from this general health context, a focused inquiry emerges regarding the relationship between bisphosphonate therapy, specifically Fosamax exposure, and the risk of osteonecrosis of the jaw. This concern represents a pivot from broad health education to a more specialized occupational and clinical exposure consideration. The shift requires careful attention to the circumstances under which patients are exposed to this medication, particularly in long-term management of bone density conditions. The occupational dimension becomes salient when considering healthcare providers, dental professionals, and patients who may encounter heightened risk due to prolonged or high-dose exposure. This transition underscores the need to move from general awareness to targeted risk assessment, without delving into specific mechanistic pathways or citing individual studies, thereby maintaining a neutral academic tone suitable for further specialized discussion.

Fosamax: Mechanism of Action and Approved Uses

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed necrotic bone in the maxillofacial region that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation typically involves pain, swelling, infection, and non-healing extraction sockets. Diagnosis is based on clinical examination and imaging, with the presence of exposed bone persisting for more than eight weeks in the absence of prior radiation therapy to the jaws.

Mechanistic Pathways and Risk Factors for ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are thought to involve the drug's potent inhibition of osteoclast activity. Bisphosphonates accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress bone remodeling. This suppression can impair the ability of the jawbone to repair microdamage and respond to local stressors like dental procedures or infection. Multiscale characterization of jawbone tissue has provided comprehensive information to help understand jawbone-specific responses to bisphosphonate-related osteonecrosis (https://pubmed.ncbi.nlm.nih.gov/40345077/). Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone and contributing to necrosis. Risk factors for developing ONJ while on Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Timeline of Exposure and Clinical Outcomes

Regarding the timeline between exposure and documented harm, the time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after stopping the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A cohort study among female patients treated for osteoporosis in the United Kingdom found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Adequacy of Warnings and Causation Considerations

The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under Section 5.4, "Osteonecrosis of the Jaw," which describes the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that the optimal duration of use has not been determined and suggests considering drug discontinuation after 3 to 5 years for low-risk patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the label does not provide specific guidance on monitoring for ONJ or routine dental evaluations before or during therapy. For affected patients, causation considerations involve evaluating the temporal relationship between Fosamax exposure and ONJ onset, excluding other causes such as radiation therapy or metastatic disease, and assessing the presence of known risk factors. The timeline between exposure and harm can range from days to years, with longer exposure associated with higher risk. Discontinuation of Fosamax may reduce risk, but the drug's long half-life in bone means that effects can persist after stopping. Patients who develop ONJ should be managed in consultation with a dental professional, and bisphosphonate therapy should be discontinued if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, Fosamax is associated with an increased risk of ONJ, particularly with longer duration of use and in the presence of risk factors such as invasive dental procedures. The prescribing information includes warnings about this risk, but the absolute risk remains low. Patients and healthcare providers should weigh the benefits of fracture reduction against the rare but serious risk of ONJ.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the relationship between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that inhibits bone resorption. A recognized adverse effect is osteonecrosis of the jaw (ONJ), a condition of exposed necrotic bone in the maxillofacial region, often associated with dental procedures or infection. The risk increases with longer duration of use and presence of risk factors such as invasive dental procedures, cancer, and concomitant therapies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How long does it take for Fosamax to cause osteonecrosis of the jaw?

The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months. A cohort study found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remain low, approximately 0.05% after 5 years.

What are the risk factors for developing ONJ while on Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does the Fosamax label include warnings about osteonecrosis of the jaw?

Yes, the prescribing information includes a specific warning under Section 5.4, "Osteonecrosis of the Jaw," describing the condition, risk factors, and management recommendations. However, it does not provide specific guidance on monitoring or routine dental evaluations before or during therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.